CCM
CLDX icon

Coldstream Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Coldstream Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-12
Closed -$218 – 1557
2025
Q1 		$218 Buy
+12
New +$268 ﹤0.01% 3479

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coldstream Capital Management's CLDX Position: Q2 2025 in Review

Coldstream Capital Management sold out of Celldex Therapeutics (CLDX) in Q2 2025, closing a stake of 12 shares — an estimated $218 sold.

Coldstream Capital Management first reported a position in CLDX in Q1 2025 and held it in 1 quarter. The position peaked at $218 in Q1 2025. 180 funds tracked by Wall St. Rank hold CLDX as of Q2 2025.

  • Coldstream Capital Management reported no remaining Celldex Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Coldstream Capital Management sold 12 Celldex Therapeutics shares in Q2 2025, an estimated $218.
  • Coldstream Capital Management first reported a position in Celldex Therapeutics in Q1 2025 and held it in 1 quarter.
  • Coldstream Capital Management's Celldex Therapeutics position peaked at $218 in Q1 2025.
  • 180 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2025.

Based on Coldstream Capital Management's 13F filing for Q2 2025, filed 12 Aug 2025.